Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Por um escritor misterioso
Descrição
Extracellular matrix and its therapeutic potential for cancer treatment
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
WO2016087994A1 - Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment - Google Patents
The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications, Molecular Cancer
Ibrutinib treatment diminishes tissue fi brosis in a PDX model of PDAC.
Pharmaceutics, Free Full-Text
Pharmaceutics, Free Full-Text
Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies - Anthony Turpin, Cindy Neuzillet, Elise Colle, Nelson Dusetti, Rémy Nicolle, Jérôme Cros, Louis de Mestier, Jean-Baptiste Bachet, Pascal Hammel, 2022
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets, Journal of Hematology & Oncology
Envisioning the immune system to determine its role in pancreatic ductal adenocarcinoma: Culprit or victim? - ScienceDirect
Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update - Cytotherapy
de
por adulto (o preço varia de acordo com o tamanho do grupo)
